Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials. by Smith, Steven G et al.
RESEARCH ARTICLE
Assay optimisation and technology transfer
for multi-site immuno-monitoring in vaccine
trials
Steven G. Smith1*, Stephanie A. Harris2, Iman Satti2, Donna Bryan3, K. Barry Walker3,
Hazel M. Dockrell1, Helen McShane2, Mei Mei Ho3
1 Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, London, United Kingdom, 2 The Jenner Institute, Oxford, United Kingdom,
3 Bacteriology Division, Medicines and Healthcare products Regulatory Agency-National Institute for
Biological Standards and Controls, South Mimms, Potters Bar, Hertfordshire, United Kingdom
* steven.smith@lshtm.ac.uk
Abstract
Cellular immunological assays are important tools for the monitoring of responses to T-cell-
inducing vaccine candidates. As these bioassays are often technically complex and require
considerable experience, careful technology transfer between laboratories is critical if high
quality, reproducible data that allows comparison between sites, is to be generated. The aim
of this study, funded by the European Union Framework Program 7-funded TRANSVAC
project, was to optimise Standard Operating Procedures and the technology transfer pro-
cess to maximise the reproducibility of three bioassays for interferon-gamma responses:
enzyme-linked immunosorbent assay (ELISA), ex-vivo enzyme-linked immunospot and
intracellular cytokine staining. We found that the initial variability in results generated across
three different laboratories reduced following a combination of Standard Operating Proce-
dure harmonisation and the undertaking of side-by-side training sessions in which assay
operators performed each assay in the presence of an assay ‘lead’ operator. Mean inter-site
coefficients of variance reduced following this training session when compared with the pre-
training values, most notably for the ELISA assay. There was a trend for increased inter-site
variability at lower response magnitudes for the ELISA and intracellular cytokine staining
assays. In conclusion, we recommend that on-site operator training is an essential compo-
nent of the assay technology transfer process and combined with harmonised Standard
Operating Procedures will improve the quality, reproducibility and comparability of data pro-
duced across different laboratories. These data may be helpful in ongoing discussions of
the potential risk/benefit of centralised immunological assay strategies for large clinical trials
versus decentralised units.
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Introduction
Immune bioassays are essential tools with which to measure the immunogenicity of vaccines.
Some of these are well established and can indicate the presence or absence of protection in
vaccinated individuals where the assay detects a reliable correlate of protection such as neutral-
ising antibody [1]. However, bioassays used to determine the immunogenicity of T-cell-induc-
ing vaccines are often more complex and require a greater degree of operator expertise and
experience. There are many T-cell effector mechanisms such as surface receptor upregulation,
cytokine secretion, proliferative capacity, degranulation and cytotoxic capabilities that may be
measured. Most T-cell assays require an antigen re-stimulation step, which is necessary to
detect vaccine-specific responses that are recognised as often representing only a small fraction
of the total T-cell compartment [2]. Some T-cell assays can simultaneously measure more than
one parameter of interest such as responder cell phenotype together with cytokine secretion
profile using flow cytometric assays or multiple secreted effector molecules using multiplex
bead array or dual/triple colour enzyme-linked immunospot (ELISpot). Others only measure
one effector function (e.g. single cytokine ELISpot or enzyme-linked immunosorbent assay
(ELISA) for interferon-gamma (IFNγ)).
With a wide array of immunological bioassays available, as well as numerous potential
modifications depending on the focus of a study, it is not surprising that a review of the litera-
ture reveals various bioassays in use, even for vaccines against a single pathogen [3–10]. There
are advantages to a more consistent and co-ordinated approach to cellular immuno-monitor-
ing within candidate vaccine trials, particularly to facilitate inter-site comparisons of the same
and different candidate vaccines and to reduce the inherent variability in data generated by
these complex assays. There is also an ongoing discussion of the merits and risks associated
with centralising immune bioassays to one laboratory, versus the complexity of comparing
data from multiple laboratory sites, this study may provide data to aid those discussions.
TRANSVAC was a European Union, Framework Program 7-funded consortium project
with the aim of accelerating the development of promising vaccine candidates by developing,
optimising and standardising state-of-the-art processes and facilities available to vaccine devel-
opers to bridge the gap between bench research and clinical assessment of novel vaccines [11].
We describe here our efforts to optimise and standardise one of these processes, namely the
monitoring of vaccine immunogenicity using bioassays. We compared three cellular immuno-
logical assays in three participating laboratories: an ELISpot assay; an intracellular cytokine
staining (ICS) assay and an ELISA assay, each designed to measure antigen-specific IFNγ.
These assays are three of the most important and commonly used assays in pre-clinical studies
and clinical trials of vaccines for tuberculosis, malaria and Human Immunodeficiency Virus
[2,12–14]. The project focussed on standard operating procedure (SOP) transfer and assay
establishment, followed by harmonisation, and assessment of performance and reproducibility
between groups. Critically, common reference standards were shared among participating lab-
oratories to enable optimisation to be better assessed, including IFNγ protein standard for
ELISA and cryopreserved donor peripheral blood mononuclear cells (PBMC) for all experi-
ments. This manuscript describes the role of SOP harmonisation and operator training in
improving inter-site reproducibility of assay performance.
Materials and methods
Study design
The main aim of the study was to compare the performance of three cellular immunological
assays across three different laboratories. The objectives were first to assess the results obtained
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using the assays when SOPs were shared between participating laboratories in their existing
format, and second to investigate what measures could be employed to improve the reproduc-
ibility of each assay. The study therefore comprised a series of three experimental “rounds”.
Operators performed round one assays in their own laboratory setting following a straightfor-
ward sharing of agreed assay SOPs and cryopreserved PBMC aliquots from healthy adult buffy
coats. Round two consisted of side-by-side training sessions during which operators per-
formed assays together in the lead laboratory for each assay to identify variability in technique
and practice not captured by the SOPs. Round three assays took place following training ses-
sions and involved operators performing assays individually in their own laboratories. In
order to strengthen the assessment of improvements in assay performance, aliquots of the
PBMC samples used in round one were used again in round three.
Donors
PBMC were chosen as the tissue for investigation as these are more easily cryopreserved and
shared between groups. Heparinised peripheral blood samples were either obtained from
healthy adult donors (for some inter-group “side-by-side” comparisons) or from local blood
transfusion services as buffy coats (all other inter-group comparisons). PBMC from these sam-
ples were cryopreserved at one laboratory and equal numbers of vials distributed to the other
two laboratories. The Ethics Committee of the London School of Hygiene and Tropical Medi-
cine (ref. 5520) and the NHS Berkshire Research Ethics Committee (REC ref. 06/Q1602/146)
gave ethical approval for the use of these samples. Informed, written consent was obtained
from adults who donated blood directly to the study.
Sample processing
PBMC were isolated from blood samples and cryopreserved in aliquots. Briefly, following isola-
tion from whole blood by density centrifugation, PBMC were counted and re-suspended in foetal
bovine serum (FBS). Cells were then chilled for 30 minutes (min) on ice after which an equal vol-
ume of chilled FBS containing 20% dimethylsulfoxide was slowly added. Cells were distributed
into Cryovials (Nunc) at 5x106 cells per tube and frozen overnight at −80˚C in Mr. Frosty contain-
ers (Nalgene) before transfer to liquid nitrogen. Prior to use, an appropriate number of cryovials
were defrosted by each operator. Vials were thawed in a 37˚C water bath until only a small bead
of ice remained. The contents were then transferred to a pre-prepared centrifuge tube containing
R10 assay medium (RPMI 1640; 10% FBS; 2 mM L-glutamine; 1% penicillin/streptomycin; 1%
sodium pyruvate, all from Sigma), centrifuged then re-suspended in R10 containing 10 units per
ml of Benzonase (Novogen). Cells were then rested at 37˚C for 2 hours (h) prior to use.
ELISA
IFNγ ELISAs were performed on supernatants generated in PBMC stimulation assays. PBMC
prepared as described above were incubated in R10 medium at 2x105 cells per well in U-bot-
tomed, 96-well plates (Costar). Antigens were added to achieve a final volume of 200 μl per
well and at concentrations of 10 μg/ml Mycobacterium tuberculosis purified protein derivative
(PPD for in vitro use, batch RT50; Statens Serum Institute) and 5 μg/ml phytohaemagglutinin
(PHA; Sigma). Medium alone was used as a negative control. After incubation for 72 h at
37˚C, supernatants were harvested and stored at −80˚C for ELISA analysis. ELISA plates were
coated overnight at 4˚C with 2 μg/ml anti-IFNγ capture antibody (BD Biosciences), washed
(phosphate-buffered saline (PBS) with 0.05% Tween 20) and blocked with PBS containing 10%
FBS for 2 h at room temperature. After a further wash, 50 μl of PBMC assay supernatant, either
undiluted or diluted to 1/3, 1/9 or 1/27, was added to wells in duplicate as was 50 μl of IFNγ
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protein standard (BD Biosciences) in doubling dilutions from 4000 pg/ml to 31.25 pg/ml and
50 μl of IFNγ positive control supernatant. Plates were incubated overnight at 4˚C, washed
and probed with anti-IFNγ-biotin (BD Biosciences), Avidin-Peroxidase (Sigma, UK) and
finally OPD Fast solution (Sigma, UK) for colour development. Plates were read at 490nm.
ELISA IFNγ concentrations were estimated from linear standard curves generated in Micro-
soft Excel by plotting optical density readings against standard concentrations. As described
previously for this ELISA method [15], the upper and lower limits of detection corresponded
to the highest and lowest standard curve values (4000 pg/ml and 32 pg/ml respectively) al-
though in this manuscript concentrations above 4000 pg/ml have been obtained and reported
following extrapolation from the standard curve. Values below the lower limit of detection
were given the value of 15.5 pg/ml (half the lower limit of detection).
ELISpot assay
ELISpot plates were pre-coated overnight at 4˚C with 15 μg/ml of anti-IFNγ coating antibody
(MabTech, Sweden) followed by washing and blocking for 2–5 h in R10 medium. PBMC were
prepared as described above and finally re-suspended at 3.75x106 cells per ml in R10. The
blocking solution was removed and PBMC added to ELISpot wells at 3x105 PBMC per well in
80 μl of R10. Stimuli and controls were prepared at appropriate concentrations in R10 and
20 μl of each stimulus added to wells in replicates of 6 (Final concentrations– 20 μg/ml PPD; 1
pg/ml Staphylococcus Enterotoxin B (SEB); 6.25 μg/ml FEC peptides (pool of 32 peptides from
Flu/EBV/CMV)). For samples from donors who on previous occasions had displayed strong
responses that produced too many spots to count, PBMC were added at half the usual number
(1.5x105 per well) for certain stimuli to achieve countable spot numbers. ELISpot plates were
incubated overnight at 37˚C then washed with PBS with 0.05% Tween 20. A biotinylated anti-
IFNγ detection antibody (Mabtech, Sweden) was added to all wells at 1 μg/ml for 2 h at room
temperature. Plates were washed again and streptavidin-alkaline phosphatase reagent (Mab-
tech, Sweden) added for 1 h at room temperature. After a final wash, plates were developed
with NBT/NCIP reagent until spots were visible. The reaction was stopped by washing plates
with tap water. After drying overnight, spots were enumerated using an automated ELISpot
reader (AID version 5.0). The same ELISpot reader, software and count settings were used at
all sites and ELISpot results were reported in spot-forming cells (SFC) per million PBMC.
ICS assay
PBMC were prepared as described above, re-suspended in R10 medium at 106 cells per ml and
distributed into 5 ml FACs tubes (Invitrogen, UK) at 106 cells per tube; one tube per stimula-
tion condition. Stimuli were added to each tube as appropriate (R10 medium as a negative
control; PPD at 20 μg/ml; SEB at 5 μg/ml; FEC peptides at 25 μg/ml) and samples were incu-
bated at 37˚C for 2 h. After this time, 3 μl of brefeldin A (BFA, Sigma, UK; stock concentration
1 mg/ml) was added to all tubes to give a final concentration of 3 μg/ml, and tubes were incu-
bated for a further 18 h (overnight) at 37˚C. Following stimulation, PBMC were washed in
FACS buffer (PBS with 0.1% bovine serum albumin (Sigma) and 0.01% sodium azide (Sigma))
and stained with VIVID live/dead reagent (Molecular Probes) as well as with a surface stain
cocktail of antibodies (anti-CD4-APC-Cy7 (Biolegend); anti-CD14-Pacific Blue (Invitrogen);
anti-CD19-Pacific Blue (eBiosciences)). After further washing, PBMC were permeabilised
with Cytofix/Cytoperm reagent (BD Biosciences) and stained with an intracellular antibody
cocktail (anti-CD3-PerCP (Biolegend); anti-CD8-FITC (Biolegend); anti-IFNγ-PE (Caltag))
prior to a final wash and re-suspension in 1% paraformaldehyde. Cells were acquired within
24 h of staining.
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Data analysis
Flow cytometric analysis was performed using FlowJo software (Treestar). Gating was per-
formed using a previously published gating strategy [16]. For all assays, averages were calcu-
lated from replicates of each condition and background measurements from negative controls
were subtracted to give final data points using Microsoft Excel. Background data (negative
control data measured in all assays, for each round and for each site) are presented as supple-
mentary data (S1 Tables). Background corrected data was plotted in Prism 7.0 (GraphPad)
and Microsoft Excel. In order to allow site-to-site assay variability to be determined by coeffi-
cients of variation (CVs), mean and standard deviation of responses measured at all 3 sites
were calculated in Microsoft Excel and are presented as summary statistics. Pre- and post-
training inter-site coefficients of variation (CVs) were compared using Mann-Whitney U tests.
Logarithmic regression analysis to determine the relationship between inter-site CVs and mag-
nitude of response measured for each assay was performed in Microsoft Excel.
Results
Initial inter-site assay comparisons using shared protocols, reagents and
stimuli
Following an initial review of different versions of assay SOPs used in each participating
laboratory, we found that SOPs for the same assay varied considerably across the groups.
Fig 1. Initial inter-site performance of assays of cellular IFNγ response. Assays measuring IFNγ
responses in stimulated PBMC were performed at three laboratory sites using shared PBMC aliquots from
three donors (D1-D3) and the indicated antigens/mitogens. Figure panels display responses measured in
each assay: ELISA (A), ELISpot (B), CD4+ T-cell ICS (C) and CD8+ T-cell ICS (D) and symbols indicate
different sites: Site 1 (squares), Site 2 (triangles), Site 3 (circles). All response measurements displayed have
been corrected for background.
https://doi.org/10.1371/journal.pone.0184391.g001
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Therefore, the optimal version of each SOP was selected and shared between sites for all fur-
ther experiments. Reagents and stimuli were also ordered centrally and shared.
A common set of frozen PBMC from three donors was used to test immune responses at three
sites. ELISA, ELISpot, CD4+ T-cell ICS and CD8+ T-cell ICS assay results are shown in Fig 1A–
1D. Mean assay responses across sites and assay CV data are shown in Table 1. Despite the use of
identical SOPs, there were still notable variations in the responses to the antigen stimuli PPD (for
all assays) and FEC (for ELISpot and ICS assays). Sites were more consistent in their measure-
ments of strong responses to the positive controls (SEB and PHA) although this varied across
Table 1. Variation in IFNγ responses measured across 3 sites.
Assay Donor Antigen Site 1 Site 2 Site 3 Mean response (SD) CV (%)
ELISA (pg/ml) A PPD 4288 3029 205 2507 (2091) 83
SEB 4089 4057 3165 3770 (525) 14
PHA 4041 3910 462 2804 (2030) 72
B PPD 3834 2106 289 2077 (1773) 85
SEB 4295 3907 1957 3386 (1253) 37
PHA 4089 3984 1409 3161 (1518) 48
C PPD 564 16 147 242 (286) 118
SEB 3967 3946 4169 4027 (123) 3
PHA 4016 3979 931 2975 (1771) 60
ELISpot (SFC) A PPD 3282 1667 73 1674 (1605) 96
FEC 1449 1607 649 1235 (514) 42
SEB 1254 772 1182 1069 (260) 24
B PPD 3269 1628 205 1701 (1533) 90
FEC 186 149 40 125 (76) 61
SEB 23 137 1065 408 (572) 140
C PPD 321 128 10 153 (157) 103
FEC 193 163 36 131 (83) 64
SEB 3 171 1069 415 (573) 138
CD4 ICS (%IFNγ+) A PPD 0.63 0.69 0.30 0.54 (0.21) 39
FEC 0.01 0.00 0.05 0.02 (0.03) 140
SEB 6.37 6.88 2.19 5.15 (2.58) 50
B PPD 0.88 1.07 0.13 0.69 (0.49) 71
FEC 0.00 0.00 0.23 0.08 (0.13) 168
SEB 6.11 7.64 1.95 5.23 (2.94) 56
C PPD 0.04 0.08 0.14 0.08 (0.05) 57
FEC 0.00 0.01 0.00 0.003 (0.004) 131
SEB 6.41 8.84 2.59 5.95 (3.15) 53
CD8 ICS (%IFNγ+) A PPD 0.05 0.00 0.01 0.02 (0.03) 145
FEC 0.46 1.25 0.79 0.83 (0.4) 48
SEB 11.39 11.39 6.70 9.83 (2.7) 28
B PPD 0.04 0.00 0.22 0.09 (0.12) 135
FEC 0.00 0.04 0.55 0.2 (0.3) 154
SEB 8.90 11.04 8.14 9.36 (1.5) 16
C PPD 0.00 0.00 0.31 0.1 (0.18) 174
FEC 0.00 0.09 0.00 0.03 (0.05) 173
SEB 7.25 10.64 7.24 8.37 (1.96) 23
Three assays, three blood donors and three antigens/positive control stimulants were used in each laboratory site to compare measured immune responses
https://doi.org/10.1371/journal.pone.0184391.t001
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different assays. For example, the ELISpot assay demonstrated a greater variation in response to
SEB. In general, there was more variation across sites when measured responses were weak. This
was particularly noticeable in situations where an antigen stimulus was sub-optimal for the induc-
tion of a response, e.g. FEC-induced CD4+ T-cell and PPD-induced CD8+ T-cell responses.
Side-by side, operator training eliminates minor variations in approach
between sites
The next step taken to eliminate inter-site variation was an “operator training” session.
Although operators at each site possessed considerable expertise and experience in performing
the assays involved, it was agreed that variations in each operator’s training, differences in SOP
interpretation, “common practice” in a given laboratory and previous experience might lead to
measurable differences when two operators’ data were compared. To counter this, each assay
was performed in a side-by-side arrangement where one operator acted as curator for a given
assay and trained the other operators in the specific individual approach of that operator to
further harmonise the technique of operators when acting alone.
As shown in Fig 2 and Table 2, consistency between results produced by each operator
improved considerably when assays were performed side-by-side in the same laboratory.
As in round one pre-training assay comparisons, inter-site assay CVs were higher when the
Fig 2. Assay responses measured during joint, inter-site training sessions. ELISA (A), ELISpot (B),
CD4+ T-cell ICS (C) and CD8+ T-cell ICS (D) assays were each performed by operators from the three
participating sites in side-by-side training sessions: Site 1 (squares), Site 2 (triangles), Site 3 (circles). For
ELISA measurements (A), assays were performed on serially diluted supernatants from PPD-stimulated
samples: PPD1, undiluted; PPD2, 1 in 3 diluted; PPD3, 1 in 9 diluted; PPD4, 1 in 27 diluted. All assays were
performed on PBMC from different, locally sourced donors. ELISPot assays were performed on 2 donors (D5
and D6). ELISA assays were performed on one donor in 2 separate repeat experiments (R1 and R2). All
response measurements displayed have been corrected for background.
https://doi.org/10.1371/journal.pone.0184391.g002
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responses measured were weaker as seen with the more diluted supernatants for the ELISA
assay (Fig 2A).
Side-by-side operator training improves future across-site consistency of
data for individually performed assays
Following the side-by-side operator training sessions, each operator working individually at
their own site repeated assays using aliquots of the same three donor PBMC described for
round one experiments. Results of this round of experiments are shown in Fig 3 and Table 3.
When all the inter-site CVs for different conditions (donor and stimulant combinations)
are compared to those from previous rounds, a reduction in the mean inter-site CV as com-
pared to the pre-training data was achieved for all assays (Fig 4). For the ELISA assay, the
post-training data maintained the level of inter-site comparability seen for the training data
and this was a significant improvement on the pre-training data (p = 0.017). Although the
ELISpot and ICS assays did not manage to maintain the level of inter-site comparability seen
when assays were performed side-by-side, a significant improvement in inter-site compara-
bility between pre- and post-training data was seen for the ELISpot assay (p = 0.039). The
improvements in CD4+ T cell and CD8+ T cell ICS assays post-training did not reach
significance.
There was a trend for both the ELISA and ICS post-training datasets, although not for the
ELISpot dataset, whereby the inter-laboratory CVs increased dramatically below a certain
magnitude of measured response (Fig 5).
TRANSVAC assay SOPs
Three detailed assay SOPs, produced as a result of the TRANSVAC project, are available
online: http://www.transvac.org/SOPimmunoassays130627.pdf
Table 2. IFNγ responses measured during “operator training” sessions.
Assay Repeat/Donor Antigen Site 1 Site 2 Site 3 Mean response (SD) CV (%)
ELISA (pg/ml) Run 1 PPD (UD) 432 383.5 352 389 (40) 10
PPD (1:3) 200 178 204 194 (14) 7
PPD (1:9) 63 50 93.5 69 (22) 32
PPD (1:27) 15.5 15.5 15.5 16 (0) 0
PHA 402.5 402.5 407 404 (3) 1
Run 2 PPD (UD) 140 133 118.5 131 (11) 8
PPD (1:3) 31 38 35.5 35 (4) 10
PPD (1:9) 15.5 15.5 21.25 17 (3) 19
PPD (1:27) 15.5 15.5 34.5 22 (11) 50
PHA 385 441 377.5 401 (35) 9
ELISpot (SFC) 1 FEC 290 256 301 282 (24) 8
PPD 65 61 69 65 (4) 6
2 FEC 9 6 8 8 (1) 17
PPD 70 74 75 73 (2) 3
CD4 ICS (%IFNg+) PPD 0.03 0.03 0.04 0.04 (0.01) 15
FEC 5.73 5.51 5.65 5.63 (0.12) 2
CD8 ICS (%IFNg+) PPD 0.92 1.07 0.94 0.98 (0.08) 8
FEC 17.05 16.30 17.09 16.81 (0.45) 3
Operators from three sites performed three assays in a side-by-side fashion for the purposes of training
https://doi.org/10.1371/journal.pone.0184391.t002
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Discussion
Previous studies have addressed the issue of immune bioassay performance across multiple
laboratories (including ELISpot, ICS and tetramer staining) and have highlighted the impor-
tance of removing protocol variations for improved inter-site comparability of data [17–20].
One of these studies also revealed that the number of years’ experience a particular laboratory
group have with an assay, does not correlate with the ability of that laboratory to perform the
assay better [17]. In agreement with that study, we also find here that guidelines and detailed
protocols can only improve assay reproducibility across laboratories up to a point. We show
that first hand observation and protocol training may achieve further improvement, even
within experienced laboratories. It is easy to envisage how a group with many years’ experience
of performing an assay might not appreciate the importance of external training of either
long-standing or new personnel, when the necessary expertise exists “in-house”. However, the
combined efforts of this and the studies referred to above demonstrate that this process should
be deemed essential in inter-laboratory harmonisation, if multiple sites are to produce compa-
rable data, irrespective of each site’s experience.
Even though the process of inter-laboratory training improved the comparability of data,
some assays harmonized more readily than others did. Performance of the IFNγ ELISA assay
Fig 3. Post-training inter-site comparison of assay performance. Following joint inter-site training
sessions, assays were repeated at the 3 participating sites using donors D1-3 as described for Fig 1. ELISA
(A), ELISpot (B), CD4+ T-cell ICS (C) and CD8+ T-cell ICS (D); symbols indicate different sites: Site 1
(squares), Site 2 (triangles), Site 3 (circles). PPD supernatants were diluted for ELISA testing (PPD1-PPD3)
as described for Fig 2. For the ELISpot assay, PPD stimulations were carried out on 2 different cell plating
densities: PPD1, 3x106 PBMC per well; PPD2, 1.5x106 PBMC per well. All response measurements
displayed have been corrected for background.
https://doi.org/10.1371/journal.pone.0184391.g003
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post-training was as consistent across sites as it had been when assays were performed side-by-
side and this was a significant improvement on inter-site comparability prior to training.
Although ELISpot assay comparability also improved significantly following training, the post-
training data was not as consistent across sites as the data produced during side-by-side assays,
despite using the same spot counting equipment, software and count settings. There was a
Table 3. Post-training variation in IFNγ responses measured across three sites.
Assay Donor Antigen Site 1 Site 2 Site 3 Mean response (SD) CV (%)
ELISA (pg/ml) A PPD (UD) 4499 4169 3833 4167 (333) 8
PPD (1:3) 1774 2171 2201 2048 (238) 12
PPD (1:9) 659 879 747 762 (110) 14
PHA 4829 4169 4107 4368 (400) 9
B PPD (UD) 3078 4183 3487 3582 (558) 16
PPD (1:3) 1211 1800 1571 1527 (297) 19
PPD (1:9) 470 755 490 572 (159) 28
PHA 4688 4183 4194 4355 (289) 7
C PPD (UD) 257 104 197 186 (77) 41
PPD (1:3) 54 16 16 28 (22) 78
PPD (1:9) 16 16 16 16 (0) 0
PHA 4096 4182 3914 4064 (137) 3
ELISpot (SFC) A PPD 1553 735 784 1024 (459) 45
PPD (1:2) 1405 892 731 1009 (352) 35
FEC 1169 933 875 992 (156) 16
B PPD 1540 779 912 1077 (406) 38
PPD (1:2) 1567 1045 1089 1233 (290) 23
FEC 174 134 133 147 (23) 16
C PPD 149 81 591 274 (277) 101
PPD (1:2) 164 80 591 278 (274) 98
FEC 214 121 151 162 (48) 29
CD4 ICS (%IFNγ+) A PPD 0.09 0.40 0.81 0.43 (0.36) 84
FEC 0.01 0.01 0.01 0.01 (0) 12
SEB 1.95 4.74 6.14 4.28 (2.13) 50
B PPD 0.13 0.40 1.21 0.58 (0.56) 97
FEC 0.01 0.01 0.01 0.01 (0) 6
SEB 1.85 5.57 6.12 4.51 (2.32) 51
C PPD 0.01 0.04 0.05 0.03 (0.021) 62
FEC 0.01 0.01 0.01 0.01 (0.003) 23
SEB 2.69 6.62 7.14 5.49 (2.43) 44
CD8 ICS (%IFNγ+) A PPD 0.06 0.01 0.01 0.03 (0.028) 101
FEC 0.23 0.86 1.44 0.84 (0.61) 72
SEB 4.10 9.01 10.00 7.7 (3.16) 41
B PPD 0.01 0.01 0.04 0.02 (0.02) 91
FEC 0.02 0.01 0.06 0.03 (0.03) 96
SEB 5.23 11.38 10.53 9.04 (3.33) 37
C PPD 0.01 0.01 0.01 0.01 (0) 0
FEC 0.02 0.04 0.09 0.05 (0.04) 71
SEB 4.25 8.70 9.20 7.38 (2.73) 37
Immune responses were tested using three assays, three blood donors and 3–4 antigens/positive control stimulants.
https://doi.org/10.1371/journal.pone.0184391.t003
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trend towards improved comparability post-training for both CD4+ T cell and CD8+ T cell
ICS assays but this did not reach statistical significance. The performance variability of the ICS
assay was also apparent in the less pronounced reduction in inter-site variability at higher
response magnitudes. Although both the IFNγ ELISA and ICS assays showed a significant
trend towards improved inter-site comparability at higher measured responses, the effect was
stronger in the former assay where inter-site CVs were below 10% at the highest measurable
responses. Even at higher measurable responses, the ICS assay did not result in inter-site CVs
of greater than 40%. One of the most likely sources of additional variability for ICS assays is
the flow cytometer instrument used, as this was the only parameter it was not possible to har-
monise across each site.
We are not aware of any studies that take a systematic look at parallel technologies for a
given biological measurement, identifying key parameters affecting concordance between and
Fig 4. Side-by-side SOP training improves inter-site assay reproducibility. Inter-site coefficients of variance across all
donors and stimulation conditions obtain both before, during and after side-by-side training were compared. Figure panels
show comparisons for ELISA (A), ELISpot (B), CD4+ T-cell ICS (C) and CD8+ T-cell ICS (D). Bars indicate mean inter-site
CV.
https://doi.org/10.1371/journal.pone.0184391.g004
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Fig 5. Lower magnitude responses are less readily measured consistently across sites for ELISA and
ICS IFNγ assays. Inter-site mean assay responses were plotted against the corresponding inter-site CVs for
ELISA (A), ELISPot (B) and ICS (C) assays. Data from CD4+ T-cell and CD8+ T-cell ICS assays were
combined. Lines are logarithmic regressions with R2 values to indicate appropriateness of fit.
https://doi.org/10.1371/journal.pone.0184391.g005
Optimising immune bioassays for clinical trials
PLOS ONE | https://doi.org/10.1371/journal.pone.0184391 October 11, 2017 12 / 15
within laboratory groups. Others have described the in-depth qualification of individual assays
similar to those we discuss in this manuscript [21,22], however this was not our aim here.
Although the current study was relatively small, we have shown that parallel comparisons can
reveal the critical aspects of each assay to focus on for better reproducibility. The use of stan-
dardised reagents, cells, reference materials and protocols, as well as staff expertise and training
are critically important to understand the underlying diversity in outcomes from a given assay.
Although this study utilised experimental reagents and tools linked to tuberculosis vaccine
research, the assays in question are equally applicable to diseases such as malaria and HIV.
However, a cost-benefit analysis will be necessary as to whether money is best spent transport-
ing all samples to a centralised analysis laboratory or on implementing the measures described
here to ensure assay comparability across multiple laboratories. A centralised approach would
ensure consistency in antigen and reagent usage, especially if the site in question was responsi-
ble for producing reference batches of these items. For example, following the current study,
there was an interruption in the supply of PPD from Statens Serum Institute, however supplies
of the same antigen from the UK National Institute for Biological Standards and Controls are
available and induce equivalent assay responses.
Our conclusions, based on the present study, are that protocol optimisation and side-by-
side training of operators may improve assay comparability across sites. However, the data
suggest that below a certain threshold of response level, cellular assays become unavoidably
variable in terms of responses measured. In addition, this effect appears to depend upon the
assay in question. Assays that measure cellular responses directly, such as ICS, are more prone
to variability. Assays such as the PBMC/IFNγ ELISA are less prone to such variations, probably
as much of the assay takes a non-cellular detection approach (i.e. antibody pairs and a protein
standard curve). These points should be borne in mind when selecting immuno-monitoring
assays for use in vaccine clinical trials. The findings of this study may also inform the ongoing
discussions on the strategies, investments and risks associated with centralising clinical
immune studies to one lab versus decentralising and the potential for extracting GCP/GLP
compliant data from multicentre studies.
Supporting information
S1 Tables. Background data as measured in unstimulated negative controls for ELISA,
ELISpot and ICS assays run at each site.
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